The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams
NCT ID: NCT02792140
Last Updated: 2017-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
32 participants
INTERVENTIONAL
2016-03-31
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Modulation of Sleep Perception Through Auditory Closed-loop Stimulation of Brain Oscillatory Activity
NCT04276064
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
NCT07082829
How do Sleeping Pills Affect Pain in the Brain?
NCT00414037
Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients
NCT00384410
Non-deceptive Application of Placebos in Insomnia
NCT03616652
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Baseline
reporting of dreams
No interventions assigned to this group
Naltrexone
daily administration of 50mg Naltrexone, reporting of dreams
Naltrexone
one week
Placebo
daily administration of Placebo, reporting of dreams
Placebo
one week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Naltrexone
one week
Placebo
one week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthiness
* Good capacity of remembering dreams
* No opiate consumption
Exclusion Criteria
* Addictive disorder
* Abnormal liver function
* Abnormal kidney function
* Hypersensitivity to active ingredient or pharmaceutical additives
* Hereditary galactose intolerance
* Lactase deficiency
* Glucose-galactose malabsorption
* Intake of opioid medication
20 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
University of Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fred Mast, Prof. Dr. phil.
Role: STUDY_DIRECTOR
Head of Cognitive Psychology, Perception and Research Methods, Dean Human Sciences Faculty, Ordinarius, University of Bern
Claudio L. Bassetti, Prof. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Chairman and Head, Department of Neurology Inselspital, Bern University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Bern
Bern, Canton of Bern, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015DR2186
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.